Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)

Mentioned by

twitter: 6 X users
facebook: 1 Facebook page

bluesky: 1 Bluesky user

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 2 Bluesky posts from 1 Bluesky users, with an upper bound of 2 followers.

Supervivencia global y seguridad a largo plazo actualizadas con ripretinib frente a sunitinib en pacientes con tumores del estroma gastrointestinal: análisis final de supervivencia global de INTRIGUE | Revista de Oncología Clínica ascopubs.org/doi/full/10…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity.